The pentavalent market size has grown steadily in recent years. It will grow from $2.53 billion in 2023 to $2.65 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth observed in the historical period can be attributed to global immunization initiatives, government vaccination programs, the prevention of multiple diseases, increased public health awareness, and international partnerships and funding.
The pentavalent market size is expected to see steady growth in the next few years. It will grow to $3.17 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The anticipated growth in the forecast period can be attributed to ongoing global immunization efforts, the expansion of vaccination programs into new geographies, increased research and development initiatives, and collaborations for improved vaccine access. Major trends in the forecast period include support from global health initiatives and funding, public awareness and education campaigns, government policies and regulatory frameworks, and technological innovations in vaccine manufacturing.
The pentavalent market is poised for growth, driven by the increasing prevalence of diphtheria. Corynebacterium diphtheriae, a bacterium causing the highly contagious and severe disease diphtheria, poses significant health challenges, including difficulties with eating, breathing, and the potential development of skin ulcers. The pentavalent vaccine offers protection against Diphtheria diseases through a 3-dose schedule of pentavalent immunization for children. This rise in the prevalence of diphtheria has led to an increased demand for pentavalent vaccines. A noteworthy example is the data reported by the World Health Organization in 2022, highlighting an unusually high number of diphtheria cases recorded through the International Health Regulations reporting process. Seven nations reported 144 instances of diphtheria, with a significant impact on asylum seekers. Clinically compatible cases constituted 69%, toxigenic diphtheria cases confirmed by laboratory testing were 31%, and 2% were suspected cases. Consequently, the escalating prevalence of diphtheria is a driving force behind the growth of the pentavalent market.
The pentavalent market is expected to experience growth, propelled by the increasing healthcare expenditure. Healthcare expenditure encompasses the total resources, both monetary and other, allocated for the provision of healthcare services within a specific timeframe. In the context of pentavalent vaccines, healthcare expenditure involves financial resources dedicated to the development, production, distribution, and administration of vaccines targeting five different diseases. In December 2023, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported a 4.1 percent increase in healthcare expenditures in the United States in 2022, reaching a total of $4.5 trillion, equivalent to $13,493 per individual. This substantial rise in healthcare expenditure is a key factor driving the growth of the pentavalent market.
Product innovation has become a prominent and widely adopted trend in the pentavalent market, with major companies actively focusing on the development of innovative products to strengthen their market positions. An illustrative example is Pfizer, a US-based pharmaceutical company operating in the pentavalent vaccines market. In December 2022, Pfizer secured approval from The United States Food and Drug Administration (FDA), a federal agency of the Department of Health and Human Services, for its Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents. This vaccine is designed to prevent meningococcal disease in individuals aged 10 to 25. The unique aspect of the MenABCWY vaccine lies in its combination of components from two vaccines into one, providing protection against the meningococcal serogroups that are responsible for the majority of invasive meningococcal diseases. This strategic product innovation reflects a commitment to addressing public health needs and advancing the effectiveness of vaccines in preventing serious illnesses.
Major companies in the pentavalent market are actively focused on developing innovative solutions, particularly in the realm of pentavalent immunization vaccines. These vaccines represent a combination designed to protect against five different diseases. A notable example is Pfizer, a US-based pharmaceutical company, which in October 2023, announced FDA approval for its 'Penbraya' pentavalent vaccine. This groundbreaking vaccine is the first and only one providing protection against the five most prevalent meningococcal serogroups - A, B, C, W-135, and Y - in individuals aged 10 through 25 years. The Penbraya vaccine incorporates elements from the Trumenba meningococcal group B vaccine and the Nimenrix meningococcal groups A, C, W-135, and Y conjugate vaccine. It has been identified as effective in offering protection against the five meningococcal serogroups responsible for the majority of global cases of invasive meningococcal disease. This signifies a strategic move towards advancing comprehensive immunization solutions to address significant public health concerns.
In January 2022, Ardian, a private equity investment firm headquartered in France, successfully completed the acquisition of Biofarma Group for an undisclosed sum. This strategic transaction positions Ardian to facilitate increased consolidation and international expansion within the market. Biofarma Group, an Italy-based entity specializing in the pentavalent vaccines market, now stands as a key asset within Ardian's portfolio, contributing to the company's broader strategic goals and market positioning.
Major companies operating in the pentavalent market report are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, LG Chem Ltd., GlaxoSmithKline PLC, Shandong Xinhua Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, PT Bio Farma (Persero), Shantha Biotechnics Limited, Seqirus Holdings PLC, Biological E. Limited, Serum Institute of India Private Limited, Indian Immunologicals Limited, Incepta Pharmaceuticals Limited, Shanghai Institute of Biological Products Co. Ltd., Changchun Changsheng Biotechnology Co. Ltd., Adimmune Corporation, AJ Vaccines, Albert David Limited, Biogenics Pvt. Ltd., GreenSignal Bio Pharma Limited, PanGen Biotech Inc., Biomed Pvt. Ltd., Maiden Pharmaceuticals Limited, Panacea Drugs Limited, Crucell N.V., Bharat Biotech International Limited, Vacsera Ltd., Vacunas Finlay S.A., Pasteur Institute of India, Zydus Cadila Healthcare Limited, EuBiologics Co. Ltd.
Asia-Pacific was the largest region in the pentavalent market in 2023. The regions covered in the pentavalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pentavalent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary types of pentavalent vaccines include sodium stibogluconate and meglumine antimoniate. Lyophilization, a method of removing water, is commonly employed to preserve perishable products, extend shelf life, or facilitate easier transportation. Formulation types encompass lyophilized and liquid variations, serving diverse applications in hospitals, pharmacies (both retail and online), and healthcare settings.
The pentavalent market research report is one of a series of new reports that provides pentavalent market statistics, including pentavalent industry global market size, regional shares, competitors with a pentavalent market share, detailed pentavalent market segments, market trends and opportunities, and any further data you may need to thrive in the pentavalent industry. This pentavalent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pentavalent market consists of sales of pentavalent vaccines such as those for diphtheria, pertussis, tetanus, hepatitis B, and Hib that treat a child against potentially fatal diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The pentavalent market size is expected to see steady growth in the next few years. It will grow to $3.17 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The anticipated growth in the forecast period can be attributed to ongoing global immunization efforts, the expansion of vaccination programs into new geographies, increased research and development initiatives, and collaborations for improved vaccine access. Major trends in the forecast period include support from global health initiatives and funding, public awareness and education campaigns, government policies and regulatory frameworks, and technological innovations in vaccine manufacturing.
The pentavalent market is poised for growth, driven by the increasing prevalence of diphtheria. Corynebacterium diphtheriae, a bacterium causing the highly contagious and severe disease diphtheria, poses significant health challenges, including difficulties with eating, breathing, and the potential development of skin ulcers. The pentavalent vaccine offers protection against Diphtheria diseases through a 3-dose schedule of pentavalent immunization for children. This rise in the prevalence of diphtheria has led to an increased demand for pentavalent vaccines. A noteworthy example is the data reported by the World Health Organization in 2022, highlighting an unusually high number of diphtheria cases recorded through the International Health Regulations reporting process. Seven nations reported 144 instances of diphtheria, with a significant impact on asylum seekers. Clinically compatible cases constituted 69%, toxigenic diphtheria cases confirmed by laboratory testing were 31%, and 2% were suspected cases. Consequently, the escalating prevalence of diphtheria is a driving force behind the growth of the pentavalent market.
The pentavalent market is expected to experience growth, propelled by the increasing healthcare expenditure. Healthcare expenditure encompasses the total resources, both monetary and other, allocated for the provision of healthcare services within a specific timeframe. In the context of pentavalent vaccines, healthcare expenditure involves financial resources dedicated to the development, production, distribution, and administration of vaccines targeting five different diseases. In December 2023, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported a 4.1 percent increase in healthcare expenditures in the United States in 2022, reaching a total of $4.5 trillion, equivalent to $13,493 per individual. This substantial rise in healthcare expenditure is a key factor driving the growth of the pentavalent market.
Product innovation has become a prominent and widely adopted trend in the pentavalent market, with major companies actively focusing on the development of innovative products to strengthen their market positions. An illustrative example is Pfizer, a US-based pharmaceutical company operating in the pentavalent vaccines market. In December 2022, Pfizer secured approval from The United States Food and Drug Administration (FDA), a federal agency of the Department of Health and Human Services, for its Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents. This vaccine is designed to prevent meningococcal disease in individuals aged 10 to 25. The unique aspect of the MenABCWY vaccine lies in its combination of components from two vaccines into one, providing protection against the meningococcal serogroups that are responsible for the majority of invasive meningococcal diseases. This strategic product innovation reflects a commitment to addressing public health needs and advancing the effectiveness of vaccines in preventing serious illnesses.
Major companies in the pentavalent market are actively focused on developing innovative solutions, particularly in the realm of pentavalent immunization vaccines. These vaccines represent a combination designed to protect against five different diseases. A notable example is Pfizer, a US-based pharmaceutical company, which in October 2023, announced FDA approval for its 'Penbraya' pentavalent vaccine. This groundbreaking vaccine is the first and only one providing protection against the five most prevalent meningococcal serogroups - A, B, C, W-135, and Y - in individuals aged 10 through 25 years. The Penbraya vaccine incorporates elements from the Trumenba meningococcal group B vaccine and the Nimenrix meningococcal groups A, C, W-135, and Y conjugate vaccine. It has been identified as effective in offering protection against the five meningococcal serogroups responsible for the majority of global cases of invasive meningococcal disease. This signifies a strategic move towards advancing comprehensive immunization solutions to address significant public health concerns.
In January 2022, Ardian, a private equity investment firm headquartered in France, successfully completed the acquisition of Biofarma Group for an undisclosed sum. This strategic transaction positions Ardian to facilitate increased consolidation and international expansion within the market. Biofarma Group, an Italy-based entity specializing in the pentavalent vaccines market, now stands as a key asset within Ardian's portfolio, contributing to the company's broader strategic goals and market positioning.
Major companies operating in the pentavalent market report are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, LG Chem Ltd., GlaxoSmithKline PLC, Shandong Xinhua Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, PT Bio Farma (Persero), Shantha Biotechnics Limited, Seqirus Holdings PLC, Biological E. Limited, Serum Institute of India Private Limited, Indian Immunologicals Limited, Incepta Pharmaceuticals Limited, Shanghai Institute of Biological Products Co. Ltd., Changchun Changsheng Biotechnology Co. Ltd., Adimmune Corporation, AJ Vaccines, Albert David Limited, Biogenics Pvt. Ltd., GreenSignal Bio Pharma Limited, PanGen Biotech Inc., Biomed Pvt. Ltd., Maiden Pharmaceuticals Limited, Panacea Drugs Limited, Crucell N.V., Bharat Biotech International Limited, Vacsera Ltd., Vacunas Finlay S.A., Pasteur Institute of India, Zydus Cadila Healthcare Limited, EuBiologics Co. Ltd.
Asia-Pacific was the largest region in the pentavalent market in 2023. The regions covered in the pentavalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pentavalent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary types of pentavalent vaccines include sodium stibogluconate and meglumine antimoniate. Lyophilization, a method of removing water, is commonly employed to preserve perishable products, extend shelf life, or facilitate easier transportation. Formulation types encompass lyophilized and liquid variations, serving diverse applications in hospitals, pharmacies (both retail and online), and healthcare settings.
The pentavalent market research report is one of a series of new reports that provides pentavalent market statistics, including pentavalent industry global market size, regional shares, competitors with a pentavalent market share, detailed pentavalent market segments, market trends and opportunities, and any further data you may need to thrive in the pentavalent industry. This pentavalent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pentavalent market consists of sales of pentavalent vaccines such as those for diphtheria, pertussis, tetanus, hepatitis B, and Hib that treat a child against potentially fatal diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Pentavalent Market Characteristics3. Pentavalent Market Trends and Strategies32. Global Pentavalent Market Competitive Benchmarking33. Global Pentavalent Market Competitive Dashboard34. Key Mergers and Acquisitions in the Pentavalent Market
4. Pentavalent Market - Macro Economic Scenario
5. Global Pentavalent Market Size and Growth
6. Pentavalent Market Segmentation
7. Pentavalent Market Regional and Country Analysis
8. Asia-Pacific Pentavalent Market
9. China Pentavalent Market
10. India Pentavalent Market
11. Japan Pentavalent Market
12. Australia Pentavalent Market
13. Indonesia Pentavalent Market
14. South Korea Pentavalent Market
15. Western Europe Pentavalent Market
16. UK Pentavalent Market
17. Germany Pentavalent Market
18. France Pentavalent Market
19. Italy Pentavalent Market
20. Spain Pentavalent Market
21. Eastern Europe Pentavalent Market
22. Russia Pentavalent Market
23. North America Pentavalent Market
24. USA Pentavalent Market
25. Canada Pentavalent Market
26. South America Pentavalent Market
27. Brazil Pentavalent Market
28. Middle East Pentavalent Market
29. Africa Pentavalent Market
30. Pentavalent Market Competitive Landscape and Company Profiles
31. Pentavalent Market Other Major and Innovative Companies
35. Pentavalent Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Pentavalent Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on pentavalent market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for pentavalent? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Type: Sodium Stibogluconate; Meglumine Antimoniate
2) By Formulation Type: Lyophilized; Liquid
3) By Application: Hospitals Pharmacies; Retail Pharmacies; Online Pharmacies
Key Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Novartis AG; Sanofi SA; Bristol-Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- Merck & Co. Inc.
- Novartis AG
- Sanofi SA
- Bristol-Myers Squibb Company
- LG Chem Ltd.
- GlaxoSmithKline plc
- Shandong Xinhua Pharmaceutical Company Limited
- Mitsubishi Tanabe Pharma Corporation
- PT Bio Farma (Persero)
- Shantha Biotechnics Limited
- Seqirus Holdings plc
- Biological E. Limited
- Serum Institute of India Private Limited
- Indian Immunologicals Limited
- Incepta Pharmaceuticals Limited
- Shanghai Institute of Biological Products Co. Ltd.
- Changchun Changsheng Biotechnology Co. Ltd.
- Adimmune Corporation
- AJ Vaccines
- Albert David Limited
- Biogenics Pvt. Ltd.
- GreenSignal Bio Pharma Limited
- PanGen Biotech Inc.
- Biomed Pvt. Ltd.
- Maiden Pharmaceuticals Limited
- Panacea Drugs Limited
- Crucell N.V.
- Bharat Biotech International Limited
- Vacsera Ltd.
- Vacunas Finlay S.A.
- Pasteur Institute of India
- Zydus Cadila Healthcare Limited
- EuBiologics Co. Ltd.
Methodology
LOADING...
